Background {#Sec1}
==========

Despite their commonly lauded role as the gold standard of causal inference and the cornerstone of evidence-based medicine, randomized controlled trials (RCT) often fail to provide evidence for individualized therapeutic decisions. Indeed, heterogeneity of treatment effects (HTE) is evident for many RCTs for many chronic conditions and for many symptoms, such that some RCT-supported treatments can have huge benefits for some patients but can be minimally effective or even harmful for others \[[@CR1], [@CR2]\]. Further, traditional, two-arm, parallel group RCTs can be costly to conduct, leaving clinicians and researchers to rely on clinical experience rather than strong experimental evidence \[[@CR3]\]. As these conventional RCTs provide only the average treatment effect of an intervention for a group of patients, patients and clinicians need additional information about the effect of a specific treatment for a specific patient for a specific problem \[[@CR2]\].

The Evidence-Based Medicine Working Group suggested that N-of-1 trials "provide the strongest evidence for the decisions of patients \[[@CR4]\]." N-of-1 trials are single-patient studies in which patients select a treatment after trying a series of treatments (i.e., multiple crossover trials) to determine the relative benefits and harms of each treatment for themselves \[[@CR1]\]. They focus on the individual patient by randomizing comparative treatments across time within each patient, rather than randomizing different patients to different comparative treatments as is done in a traditional RCT. Thus, instead of using the results of a conventional or between-patient RCT to choose the best treatment for a patient, the N-of-1 trial methodology can provide scientifically valid results and therefore valuable information in a practical manner that can be used by patients and providers to decide upon a personally optimal treatment and so overcome HTE. In this way, N-of-1 trials are the foundational design for a truly patient-centered comparative effectiveness method. Further, N-of-1 trials are specifically designed to help patients make healthcare decisions that are informed by high-integrity, evidence-based information that is uniquely relevant to their important outcomes and values \[[@CR5]\]. In a series of demonstration trials, N-of-1 designs have led to valuable changes in treatment, cessation of treatment, or confirmation of the original treatment \[[@CR6]--[@CR10]\]. For example, in one series of 71 N-of-1 trials for patients with either chronic pain or osteoarthritis, 46 patients (65 %) decided to change their pain medication as a result of the information from the trials, and of the 37 patients using an NSAID or Cox-2 inhibitor drug for pain management before their trials, 12 (32 %) decided that the medication was not helping and stopped it, as a result of their trial results.

Notwithstanding the proliferation of N-of-1 trials in the medical literature, randomized N-of-1 trials have only sporadically been used for treatments that target psychological or health behavior outcomes. Furthermore, among those N-of-1 studies that have considered psychological or health behavior outcomes, information regarding study quality and methods for assessing study quality is limited. This gap in knowledge is peculiar given the abundance of other single participant study designs (e.g., ABA designs, multiple baseline designs, and time-series designs) in the psychology literature and the push to tailor psychological interventions to the individuality of the patient and the singularity of his or her context and condition \[[@CR11]\]. It is with these gaps in knowledge in mind that we endeavored to conduct a systematic review of N-of-1 trials of interventions with psychological or health behavior endpoints.

Methods/Design {#Sec2}
==============

Aims {#Sec3}
----

The proposed review aims to describe the interventions and outcomes and assess the quality of N-of-1 trials for psychological or health behavior outcomes. The reporting of this review will conform to Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines \[[@CR12]\].

Eligibility criteria {#Sec4}
--------------------

Population: This review is not limited to a particular population, but will consider all populations for whom N-of-1 trials have been conducted.

Interventions: All medical, psychological, and behavioral interventions for which N-of-1 trials have been conducted (i.e., no restrictions on interventions) will be considered.

Comparator/control: Inclusion criteria require placebo control or an active treatment control.

Outcomes: Psychological and health behavior outcomes will be considered in the following categories:Behavioral---defined as a response that can be conditioned and is objectively observable (e.g., number of steps).Self-perceived disease severity or disease processes---defined as patient ratings of disease severity or disease processes, including but not limited to pain, dyspnea, and gastrointestinal discomfort.Psychological---defined as self-reported affective functioning, including but not limited to depression and anxiety.

Study design {#Sec5}
------------

Only peer-reviewed studies in full text, conference abstract, or doctoral dissertations are eligible for this review. Studies must involve randomization of treatments within blocks or pairs, crossover of interventions, individual patients or series of patients, and single patients as the unit of analysis.

Exclusion {#Sec6}
---------

Studies that do not contain sufficient trial detail, consist primarily of methods and review (e.g., Lillie and colleagues \[[@CR13]\] discuss design issues and the analysis of N-of-1 trials but do not report an N-of-1 trial of their own), and/or are not written in English will be ineligible as these will make assessment of study quality impossible.

Search strategy {#Sec7}
---------------

Potentially relevant articles will be identified by searching the biomedical electronic databases Ovid MEDLINE, EMBASE, all six databases in The Cochrane Library, CINAHL, and PsycINFO. All relevant subject headings and free-text terms will be used to represent N-of-1 controlled trials and psychological or behavioral interventions, and databases will be searched from inception through the week of planned manuscript submission. Terms for MEDLINE will include the following: n-of-1.tw OR ((individual or single) adj (patient\$ or participant\$ or subject\$)).tw. OR ipd.tw AND exp Behavioral Medicine/OR exp psychotherapy/OR behavio\$ adj (change or health or medicine or therap\$)).tw OR psychotherap\$.tw. OR psycholog\$.tw. (see Additional file [1](#MOESM1){ref-type="media"}: for full strategies). These terms will be adapted for the other databases. Ongoing studies will also be sought through Clinicaltrials.gov and the WHO International Clinical Trials Registry Platform. Additional records will be identified by scanning the reference lists of relevant studies and reviews, by employing the Related Articles feature in PubMed, and by using the Cited Reference Search in Scopus.

Search selection process {#Sec8}
------------------------

Two reviewers (JAS, LF) will independently screen titles and abstracts of all the retrieved bibliographic records. Full texts of potentially eligible records passing the title and abstract screening level will be retrieved and examined independently by the two reviewers according to the above mentioned eligibility criteria. Disagreements at both screening levels (title/abstract and full text) will be adjudicated by a third reviewer (KWD). A PRISMA flow chart will outline the study selection process and reasons for exclusions.

Assessment of study quality {#Sec9}
---------------------------

Assessment of study quality will be performed by two reviewers (JAS, LF) according to the Consolidated Standards of Reporting Trials (CONSORT) statement \[[@CR14]\] and the CONSORT extension for N-of-1 Trials (CENT) (Table [1](#Tab1){ref-type="table"}) \[[@CR15]\]. After determination of a study's eligibility, the following information will be reviewed and determined to be either reported or not reported: introduction (scientific background and explanation of rationale, specific objectives or hypotheses, rationale for using an N-of-1 approach), trial design characteristics (description of trial design with planned number of periods and duration of each period, individualization of the design for series of participants, important changes to methods after trial commencement, participant eligibility criteria, duration of treatment periods), intervention and outcome characteristics with sufficient detail to allow replication (completely defined primary and secondary endpoints, measurement properties of outcome assessment tools, changes to trial outcomes), allocation characteristics (allocation method, blinding, allocation concealment mechanism, allocation implementation), statistical analytic methods (sample size determination, explanation of interim analyses and stopping guidelines, consideration of carry-over effects, period effects, intra-participant associations, and methods of quantitative synthesis of series data), results (number and sequence of periods completed, number of participants enrolled and assigned to intervention, losses or exclusion of participations after treatment assignment, table showing baseline data, number of periods analyzed, number of trials for which data were synthesized, results for each primary and secondary endpoint per period, estimated effect size and precision, results of any additional analyses), harms or unintended effects for the intervention, and discussion (trial limitations, generalizability, consideration of harms and benefits).Table 1CENT 2015 checklist: CONSORT 2010 checklist items with modifications or additions for individual or series of N-of-1 trials \[[@CR15]\]Section/topicItem no.CONSORT 2010Item no.CENT 2015Title and abstract1aIdentification as a randomized trial in the title1aIdentification as an "N-of-1 trial" in the titleFor series: identification as "a series of N-of-1 trials" in the title1bStructured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)1bIntroductionBackground and objectives2aScientific background and explanation of rationale2bSpecific objectives or hypotheses2cRationale for using N-of-1 approachMethodsTrial design3aDescription of trial design (such as parallel, factorial) including allocation ratio3aDescribe trial design, planned number of periods, and duration of each period (including run-in and wash out, if applicable)In addition for series: whether and how the design was individualized to each participant and explanation of the series design3bImportant changes to methods after trial commencement (such as eligibility criteria), with reasonsParticipant(s)4aEligibility criteria for participants4aDiagnosis/disorder, diagnostic criteria, comorbid conditions, and concurrent therapies.For series: same as CONSORT item 4a4bSettings and locations where the data were collected4cWhether the trial(s) represents a research study and if so, whether institutional ethics approval was soughtInterventions5The interventions for each group with sufficient details to allow replication, including how and when they were actually administered5The interventions for each period with sufficient details to allow replication, including how and when they were actually administeredOutcomes6aCompletely defined pre-specified primary and secondary outcome measures, including how and when they were assessed6a.1Description and measurement properties (validity and reliability) of outcome assessment tools6bAny changes to trial outcomes after the trial commenced, with reasonsSample size7aHow sample size was determined7bWhen applicable, explanation of any interim analyses and stopping guidelinesRandomizationSequence generation8aMethod used to generate the random allocation sequence8aWhether the order of treatment periods was randomized, with rationale, and method used to generate allocation sequence8bType of randomization; details of any restriction (such as blocking and block size)8bWhen applicable, type of randomization; details of any restrictions (e.g., pairs, blocking)8cFull, intended sequence of periodsAllocation concealment mechanism9Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assignedImplementation10Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventionsBlinding11aIf done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how11bIf relevant, description of the similarity of interventionsStatistical methods12aStatistical methods used to compare groups for primary and secondary outcomes12aMethods used to summarize data and compare interventions for primary and secondary outcomes12bMethods for additional analyses, such as subgroup analyses and adjusted analyses12bFor series: if done, methods of quantitative synthesis of individual trial data, including subgroup analyses, adjusted analyses, and how heterogeneity between participants was assessed, (for specific guidance on reporting syntheses of multiple trials, please consult the PRISMA Statement)12cStatistical methods used to account for carry-over effect, period effects, and intra-subject correlationResultsParticipant flow (a diagram is strongly recommended)13aFor each group, the numbers of participants who were randomly assigned, received intended treatment, and were analyzed for the primary outcome13a.1Number and sequence of periods completed and any changes from original plan with reasons13a.2For series: the number of participants who were enrolled, assigned to interventions, and analyzed for the primary outcome13bFor each group, losses and exclusions after randomization, together with reasons13cFor series: losses or exclusion of participants after treatment assignment, with reasons, and period in which this occurred, if applicableRecruitment14aDates defining the periods of recruitment and follow-up14bWhy the trial ended or was stopped14bWhether any periods were stopped early and/or whether trial was stopped early, with reason(s)Baseline data15A table showing baseline demographic and clinical characteristics for each groupNumbers analyzed16For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups16For each intervention, number of periods analyzedIn addition for series: if quantitative synthesis was performed, number of trials for which data were synthesizedOutcomes and estimation17aFor each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95 % confidence interval)17a.1For each primary and secondary outcome, results for each period; an accompanying figure displaying the trial data is recommended17a.2For each primary and secondary outcome, the estimated effect size and its precision (e.g., 95 % confidence interval)In addition for series: if quantitative synthesis was performed, group estimates of effect and precision for each primary and secondary outcome17bFor binary outcomes, presentation of both absolute and relative effect sizes is recommendedAncillary analyses18Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory18Results of any other analyses performed, including assessment of carry-over effects, period effects, intra-subject correlationIn addition for series: if done, results of subgroup or sensitivity analysesHarms19All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)19All harms or unintended effects for each intervention (for specific guidance see CONSORT for harms)DiscussionLimitations20Trial limitations, addressing sources of potential bias, imprecision, and if relevant, multiplicity of analysesGeneralizability21Generalizability (external validity, applicability) of the trial findingsInterpretation22Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidenceOther informationRegistration23Registration number and name of trial registryProtocol24Where the full trial protocol can be accessed, if availableFunding25Sources of funding and other support (such as supply of drugs), role of funders

Extraction of study endpoints {#Sec10}
-----------------------------

Type of study endpoint (e.g., self-report rating scale, objectively observed behaviors) will be recorded by two independent reviewers (JAS, LF). Extraction data for 20 % of studies will be compared between reviewers to ensure accuracy of data extraction. Review of these outcomes is intended to provide clinicians and researchers with information that may be of use as they design their own N-of-1 trials by allowing them to identify clinical conditions and outcomes that may be particularly amenable to N-of-1 methodology.

Discussion {#Sec11}
==========

This systematic review aims to add to the extant literature by reviewing data concerning N-of-1 randomized trials with psychological and health behavior outcomes. Our review considers a wide variety of interventions and psychological and health behavior outcomes including, but not limited to, complementary and alternative medicine interventions, psychopharmacologic interventions, surgical interventions, behavioral interventions, and psychotherapeutic interventions. The findings will need to be considered alongside the plethora of other single-case designs that have dominated the fields of psychology and medicine to ensure their uniqueness. The findings might therefore serve as a springboard from which other N-of-1 trials could be developed and may minimize the tendency for researchers to miss reporting critical information required to understand the body of evidence available on any one topic.

There are several limitations that will contextualize the findings and generalizability of the proposed review including our a priori decision to not quantitatively aggregate results. We made this decision as we expect disparate outcomes, time periods, and types of interventions across all behavioral and psychological domains. Moreover, we have chosen to exclude reports that contain insufficient trial detail, which limits the scope of this review. This limitation is important as many N-of-1 trials are embedded within larger editorial, review, and other articles, and their exact methodology is likely not ascertainable. Finally, N-of-1 trials themselves may be limited due to the limited resources available to most practitioners. Nonetheless, their advantages over open trials of treatment are obvious, and services to conduct single-patient trials are becoming more available \[[@CR16]\].

In conclusion, although parallel-arm, between-person RCTs are the sine qua non of causal inference, there exist additional randomized designs that are useful in certain circumstances, such as when HTE is large and when the symptoms or outcomes can be measured within-person, and the treatment is reversible. N-of-1 trials offer a low-cost means under these circumstances by which to overcome HTE, particularly by allowing for individualization of treatment. Although a previous systematic review has examined N-of-1 trials in the medical literature \[[@CR1]\], a review of their use for interventions with psychological and health behavior outcomes in particular is lacking. The proposed review will thus help summarize the available evidence qualitatively and may guide the development of new N-of-1 trials.

Additional file {#Sec12}
===============

Additional file 1:**Search strategy.** Detailed search strategy proposed for the systematic review.

RCT

:   randomized controlled trial

HTE

:   heterogeneity of treatment effect

PRISMA

:   Preferred Reporting Items for Systematic Reviews and Meta-analyses

CONSORT

:   Consolidated Standards of Reporting Trials

CENT

:   CONSORT Extension for N-of-1 Trials
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